An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin

Journal of Immunological Methods

Volumn 210, Issue 2, 1997, Pages 137-148

  Tardi, Paul G ^a   Swartz, Erik N ^c   Harasym, Troy O ^b,c   Cullis, Pieter R ^b   Bally, Marcel B ^b,c  

^a Inex Pharmaceuticals Corporation   (Canada)

^b Dept Biochem Molec Biol U   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Doxorubicin; Drug targeting; Humoral immunity; Immune suppression

Indexed keywords

DISTEAROYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; LIPOSOME; MACROGOL; OVALBUMIN;

ANIMAL EXPERIMENT; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG TARGETING; FEMALE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IMMUNOREACTIVITY; INTRAVENOUS DRUG ADMINISTRATION; MICROENCAPSULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODY FORMATION; DOXORUBICIN; DRUG CARRIERS; IMMUNOTOXINS; LIPOSOMES; MICE; MICE, INBRED C3H; OVALBUMIN;

ANIMALIA;

EID: 0031590665     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(97)00178-6     Document Type: Article

References (32)

1. Ahmad I., Longenecker M., Samuel J., Allen T.M. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 53:1993;1484-1488.
2. Alving C.R. Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods. 140:1991;1-13.
3. Bally M.B., Nayar R., Masin D., Cullis P.R., Mayer L.D. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother. Pharmacol. 27:1990;13-19.
4. Bally M.B., Nayar R., Masin D., Hope M.J., Cullis P.R., Mayer L.D. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim. Biophys. Acta. 1023:1990;133-139.
5. Bally, M.B., Mayer, L.D., Hope, M.J., Nayar, R., 1993. Pharmacodynamics of liposomal drug carriers: Methodological considerations. In: Gregoriadis, G. (Ed.), Liposome Technology, 2nd ed. CRC Press, Inc., Boca Raton, FL, vol. 3, pp 27- 41.
6. Boeckler C., Frisch B., Muller S., Schuber F. Immunogenicity of new heterobifunctional cross-linking reagents used in the conjugation of synthetic peptides to liposomes. J. Immunol. Methods. 191:1996;1-10.
7. Brewer J.M., Richmond J., Alexander J. The demonstration of an essential role for macrophages in the in vivo generation of IgG2a antibodies. Clin. Exp. Immunol. 97:1994;164-171.
8. Daemen T., Hofstede G., Ten Kate M.T., Bakker-Woudenberg I.A., Scherphof G.L. Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages. Int. J. Cancer. 61:1995;716-721.
9. Dal Monte P., Szoka F.C. Effect of liposomal encapsulation on antigen presentation in vitro. Comparison of presentation by peritoneal macrophages and B cell tumors. J. Immunol. 142:1989;1437-1443.
10. Derksen J.T.P., Morselt H.W.M., Scherphof G.L. Processing of different liposomal markers after in vivo uptake of immunoglobulin-coated liposomes by rat liver macrophages. Biochim. Biophys. Acta. 931:1987;33-40.
11. Harasym T.O., Tardi P., Longman S.A., Ansell S.M., Bally M.B., Cullis P.R., Choi L.S.L. Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjugate Chem. 6:1995;187-194.
12. Hope M.J., Bally M.B., Webb G., Cullis P.R. Production of large unilamellar vesicles by a rapid extrusion procedure: Characterization of size, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta. 812:1985;55-65.
13. Khazaeli M.B., Conry R.M., LoBuglio A.F. Human immune response to monoclonal antibodies. J. Immunother. 15:1994;42-52.
14. Ledermann J.A., Begent R.H., Bagshawe K.D., Riggs S.J., Searle F., Glaser M.G., Green A.J., Dale R.G. Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br. J. Cancer. 58:1988;654-657.
15. Longman S.A., Tardi P.G., Parr M.J., Choi L., Cullis P.R., Bally M.B. Accumulation of protein-coated liposomes in an estravascular site: Influence of increasing carrier circulation lifetimes. J. Pharm. Exp. Ther. 275:1995;1177-1184.
16. Loughrey H.C., Choi L.S., Cullis P.R., Bally M.B. Optimized procedures for the coupling of proteins to liposomes. J. Immunol. Methods. 132:1990;25-35.
17. Mayer L.D., Hope M.J., Cullis P.R., Janoff A.S. Solute distribution and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochim. Biophys. Acta. 817:1985;193-196.
18. Mayer L.D., Bally M.B., Cullis P.R. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim. Biophys. Acta. 857:1986;123-126.
19. Mayer L.D., Tai L.C.L., Bally M.B., Mitilenes G.N., Ginsberg R.S., Cullis P.R. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim. Biophys. Acta. 1025:1990;143-151.
20. Nair S., Babu J.S., Dunham R.G., Kanda P., Burke R.L., Rouse B.T. Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. J. Virol. 67:1993;4062-4069.
21. Parr M.J., Bally M.B., Cullis P.R. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim. Biophys. Acta. 1168:1993;249-252.
22. Parr M.J., Ansell S.M., Choi L.S., Cullis P.R. Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim. Biophys. Acta. 1195:1994;21-30.
23. Parr M.J., Masin D., Cullis P.R., Bally M.B. Accumulation of liposomal lipid and encapsulated doxorubicin in murine lewis lung carcinoma: The lack of beneficial effects by coating liposomes with poly(ethylene glycol). J. Pharm. Exp. Therap. 280:1997;1319-1327.
24. Phillips N.C., Dahman J. Immunogenicity of immunoliposomes: Reactivity against species-specific IgG and liposomal phospholipids. Immunol. Lett. 45:1995;149-152.
25. Phillips N.C., Gagne L., Tsoukas C., Dahman J. Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status. J. Immunol. 152:1994;3168-3174.
26. Shek P.N., Lukovich S. The role of macrophages in promoting the antibody response mediated by liposome-associated protein antigens. Immunol. Lett. 5:1982;305-309.
27. Shek P.N., Heath T.D. Immune response mediated by liposome-associated protein antigens. III. Immunogenicity of bovine serum albumin covalently coupled to vesicle surface. Immunology. 50:1983;101-106.
28. Shek P.N., Lopez N.G., Heath T.D. Immune response mediated by liposome-associated protein antigens IV. Modulation of antibody formation by vesicle-encapsulated methotrexate. Immunology. 57:1986;153-157.
29. Shockley T.R., Lin K., Nagy J.A., Tompkins R.G., Yarmush M.L., Dvorak H.F. Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenographs. Cancer Res. 52:1992;367-376.
30. Su D., van Rooijen N. The role of macrophages in the immunoadjuvant action of liposomes; Effect of elimination of splenic macrophages on the immune response against intravenously injected liposome-associated albumbin antigen. Immunology. 66:1989;466-470.
31. Vidal C., Quintela A.G., Cuervas-Mons V. Influenence of Kupffer cell phagocytosis blockade on the production of ovalbumin-specific IgE and IgG1 antibodies in an experimental model. Clin. Exp. Allergy. 23:1993;15-20.
32. Vitetta E.S., Uhr J.W. Monoclonal antibodies as agonists: An expanded role for their use in cancer therapy. Cancer Res. 54:1994;5301-5309.